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Abstract: Roux-en-Y gastric bypass surgery (RYGB) reverses type 2 diabetes (DM2) in 
approximately 83% of patients with morbid or severe obesity. This procedure has been per-
formed in small numbers of severely obese patients with type 1 diabetes (DM1), but the impact 
on glycemic control and insulin requirement in this population has not been widely described. 
We report three patients with DM1 and severe obesity that underwent RYGB. Weight, glyce-
mic control, and insulin requirements before and one year after the procedure were compared. 
Significant weight loss was achieved by all three patients but insulin requirements decreased in 
only 2 patients. In contrast, glycemic control (A1C) remained suboptimal in all three patients 
up to one year after the surgery. These findings suggest that RYGB leads to important weight 
loss and positively affects insulin sensitivity. However, reaching optimal glycemic control in 
patients with DM1 diabetes remains challenging due to persisting insulin deficiency.
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Introduction
Obesity is commonly found in patients with type 2 diabetes (DM2). This growing 
epidemic has also affected populations with type 1 diabetes (DM1). Recently, the 
prevalence of obesity in the United States among young patients (3–19 years old) 
with DM1 was found to be over 12%.1 For patients with DM2 and morbid or severe 
obesity, defined as body mass index (BMI) over 40 kg/m2, bariatric surgery has resulted 
in reversal of type 2 DM in approximately 83% of cases.2 Of the available bariatric 
surgical techniques, diabetes reversal ranges from 66% after gastric banding to 95% 
with the biliopancreatic diversion with duodenal switch (BPD).3 There is increasing 
evidence that in addition to caloric restriction, significant changes in secretion of gut 
peptides or incretins occur with surgery leading to important enhancement of insulin 
production and utilization.4
In contradistinction to DM2, results of these procedures in severely obese patients 
with DM1 are limited. Czupryniak et al presented two cases of severely obese patients 
with DM1 who underwent Roux-en-Y gastric bypass surgery (RYGB). They reported 
remarkable improvement of glycemic control based on a decrease in glycosylated 
hemoglobin (A1C) of 9.5% to 5.7% in the first case and 10.4% to 7.3% in the second 
case. These authors suggested that RYGB led to improvement in insulin resistance, 
favorably affecting glycemic control. Nevertheless, insulin therapy was still required 
after 2 years in both cases although the insulin requirement decreased from 0.6 units/kg Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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to 0.5 units/kg in the first case and from 0.95 units/kg to 
0.78 units/kg in the second case.5
Case reports
We retrospectively gathered data on three female patients 
with the diagnosis of DM1 with severe obesity that electively 
underwent RYGB. The first patient (Patient A) was a 29-year-
old female with a history of DM1since age 21. Her diagnosis 
was confirmed by undetectable C-peptide (,0.1 ng/mL) 
and elevated glutamic acid decarboxylase autoantibodies 
(GAD-65) at 4.1 nmol/L. Since her last pregnancy at age 23, 
her weight significantly increased to maximum preoperative 
weight of 115 kg (BMI 40.6 kg/m2). She was unable to lose 
weight by lifestyle changes and was successfully screened 
for RYGB. Her average A1C the year before RYGB surgery 
reflected poor glycemic control (8.2%). Insulin was delivered 
through a continuous subcutaneous infusion system (CSII). 
Her total daily insulin dose before the surgery was 65.5 units, 
(0.57 units/kg). Within the first month after the RYGB surgery, 
her insulin requirements decreased to 0.37 units/kg without 
much prandial insulin on a very minimal diet. However, as her 
diet advanced, prandial insulin doses were reintroduced. One 
year after the procedure her weight had decreased to 75.5 kg 
corresponding to a 34.4% weight reduction. Her total insulin 
dose was 45 units (0.60 units/kg). Her average A1C for the 
year after the surgery decreased to 7.5%.
The second patient (Patient B) was a 62-year-old female 
who had been diagnosed with DM1 since age 9. Undetectable 
C-peptide (,0.05 ng/mL) was documented in her records con-
firming her diagnosis. Other comorbidities included depression, 
dyslipidemia, and history of stroke. She had a preoperative 
weight of 110.4 kg (BMI 43.9 kg/m2). Her insulin was delivered 
through a CSII system. Her total daily insulin dose prior to 
RYGB was 52.2 units (0.47 units/kg). Her average preoperative 
A1C was 7.6%. One year after the procedure her weight had 
decreased to 77.5 kg (29.8% weight reduction). Her total daily 
insulin dose had decreased to 35.6 units (0.46 units/kg). Her 
average A1C for the year after the surgery was 7.8%.
The third patient (Patient C) was a 36-year-old female with 
a history of DM1 since age 22. Her diagnosis was supported 
by undetectable C-peptide (,0.05 ng/mL). She had history of 
obesity for at least 10 years before she was successfully sched-
uled for a RYGB. At the time of her procedure her weight was 
166.7 kg (BMI 53.2 kg/m2). She used a multiple daily injection 
insulin regimen. Her total daily insulin dose was 180 units 
(1.08 units/kg). Her average A1C for the year before the surgery 
was 8.1%. At one-year post procedure, her weight decreased to 
96.4 kg for a 42.1% weight reduction. Her insulin requirements 
had decreased to a total daily dose of approximately 48.2 units 
(0.5 units/kg). Her average A1C for the year after the procedure 
increased to 8.8% (Tables 1 and 2).
Discussion
The striking results of bariatric surgery on severely obese 
patients with DM2 have brought into question traditional theo-
ries on the pathogenesis and therapeutics of diabetes mellitus. 
Complete resolution of this chronic condition is now the norm 
rather than the exception in severely obese patients that undergo 
bariatric procedures. Extending these benefits to patients with 
DM1 has created significant interest in this field.
The mechanisms leading to resolution of DM2 after 
RGYB are not clearly understood. Growing research has 
offered several important facts and proposed theories to 
better understand this phenomenon. Different bariatric tech-
niques achieve different rates of DM2 diabetes resolution, 
with the most impressive results obtained from the partial 
gastrectomy with distal Roux-en-Y reconstruction (RYGB) 
and the BPD. Common endpoints of these techniques that 
use bypass procedure are rapid delivery of gastric content 
to the distal ileum and exclusion of proximal small intestine 
from the food path. Rapid delivery of gastric content to the 
distal part of the small intestine has been associated with 
increased secretion of gut hormones also known as incretins. 
This concept also known as the hindgut theory proposes 
that incretins, especially glucagon-like peptide (GLP-1) and 
peptide YY (PYY), contribute in great part to the improved 
Table  1  Characteristics  of  patients  before  Roux-en-Y  gastric 
bypass surgery
Patient A Patient B Patient C
Preoperative weight (kg) 115.0 110.4 166.7
Preoperative BMI (kg/m2) 40.6 43.9 53.28
Preoperative insulin  
requirements (units/kg)
0.57 0.47 1.08
C-peptide (ng/mL) ,0.1 ,0.05 ,0.05
Average preoperative A1C (%) 8.2 7.6 8.1
Abbreviations: A1C    , glycosylated hemoglobin; BMI, body mass index.
Table  2  Characteristics  of  patients  after  Roux-en-Y  gastric 
bypass surgery
Patient A Patient B Patient C
Postoperative weight (kg) 75.5 77.5 96.4
Postoperative BMI (kg/m2) 26.7 30.8 30.8
Postoperative insulin  
requirements (units/kg)
0.60 0.46 0.50
Average postoperative A1C (%) 7.5 7.8 8.8
Abbreviations: A1C, glycosylated hemoglobin; BMI, body mass index.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
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metabolic control seen in the postoperative period.4 These 
two substances produced by the L cells of the distal ileum are 
known to have important metabolic actions. Given the smaller 
plasma concentration of GLP-1 compared to PYY, GLP-1 
is considered to be more potent. Several beneficial effects 
have been attributed to GLP-1. Induced satiety through slow 
gastric emptying and action on the central nervous system 
has been linked to significant weight loss. More importantly, 
GLP-1 has been associated with increased insulin secretion 
by acting directly over the beta cell membrane receptors. 
GLP-1 also increases glycogenesis in hepatic and skeletal 
muscle cells. It also accelerates lipogenesis in adipocytes, 
which may result in improved insulin sensitivity.6 In addition, 
it has been shown in animal models with DM2, that GLP-1 
increased beta-cell mass through regulation of proliferation, 
neogenesis, and apoptosis.7 This last quality of GLP-1 would 
suggest a hopeful scenario for patients with DM1 of whom 
their residual beta cell mass is mostly minimal or absent.
A different theory originally proposed by Pories and 
later explored by Rubino et al known as the ‘foregut bypass’ 
hypothesis, suggests that the exclusion of the duodenum 
and proximal jejunum from the gastrointestinal tract seems 
to prevent the secretion of a deleterious hormone (decretin) 
that could be implicated in the pathogenesis of diabetes.8,9 
As to our knowledge, in despite of extensive research in this 
area, no substance has been identified yet.
Insulin sensitivity has been shown to notoriously improve 
after RYGB. Bikman et al suggested that something other than 
the weight loss contributed in great part for the change in insulin 
utilization. They proposed that improved insulin sensitivity and 
greater glucose transport is related to reduced inhibition of κB 
kinase β activity and enhanced insulin signaling in muscle.10
In this small series of patients with DM1 diabetes, the 
RYGB bariatric procedure did not appear to significantly 
improve glycemic control. One year after the procedure, A1C 
was still not at goal for any of the three patients. Insulin require-
ments did decrease for two patients suggesting improved 
insulin sensitivity, while it remained unchanged in one.
We hypothesize that the resolution of DM2 after RGYB 
requires significant functioning beta cells mass. In DM1 where 
insulin secretion is minimal or often absent, RGYB is less 
likely to positively impact glycemic control. Dependence of 
exogenous insulin therapy to achieve euglycemia precludes 
easily achieving optimal glycemic control in this patient 
population.
Conclusion
The RYGB bariatric procedure seems not to directly improve 
glycemic control in DM1. Achieving glycemic control is 
challenging in these patients even after decreasing their 
excess body weight and improving insulin sensitivity. Larger 
randomized case control studies are needed to demonstrate 
more definitive results.
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